BioLight Life Sciences Ltd. (TLV: BOLT)

Market Cap	21.42M
Revenue (ttm)	198.00K
Net Income (ttm)	-6.16M
Shares Out	4.66M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,205
Open	478.80
Previous Close	478.80
Day's Range	459.00 - 478.80
52-Week Range	4.40 - 720.00
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2024

About BioLight Life Sciences

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company’s ophthalmic product offering and pipeline of product candidates include DiagnosTear’s TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 4
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BOLT

Financial Performance

In 2023, BioLight Life Sciences's revenue was 118,000, an increase of 87.30% compared to the previous year's 63,000. Losses were -26.02 million, 231.6% more than in 2022.